Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088. The study aims to evaluate the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also examines the drug-drug interaction between ABBV-1088 and itraconazole in Western participants, which is crucial for understanding the compound’s potential in diverse populations.
The study tests ABBV-1088, an oral capsule, across multiple doses and in combination with itraconazole. The intervention’s primary goal is to assess its pharmacokinetic profile and interactions, providing foundational data for further development.
The study employs a randomized, parallel assignment model with triple masking to ensure unbiased results. Its primary purpose is basic science, focusing on understanding the drug’s behavior in the body.
Key dates for the study include its start on August 28, 2024, with the latest update on September 9, 2025. The study is currently suspended, which is significant for stakeholders tracking its progress and potential market entry.
The suspension of this study may impact AbbVie’s stock performance and investor sentiment, as delays in clinical trials can affect projected timelines for drug approval and market entry. Competitors in the pharmaceutical industry may gain a temporary advantage, depending on their pipeline progress and market strategies.
The study remains ongoing, with further details available on the ClinicalTrials portal.